Topics

FDA Clears Ozanimod (Zeposia) for MS; COVID-19 Delays Launch

07:53 EDT 26 Mar 2020 | Medscape

Ozanimod is the first oral, once-daily sphingosine-1-phosphate receptor modulator approved for adults with relapsing forms of multiple sclerosis.
FDA Approvals

Original Article: FDA Clears Ozanimod (Zeposia) for MS; COVID-19 Delays Launch

NEXT ARTICLE

More From BioPortfolio on "FDA Clears Ozanimod (Zeposia) for MS; COVID-19 Delays Launch"

Quick Search